01801 INNOVENT BIO
- 35.800
- -1.000-2.72%
INNOVENT BIO News
Overview of the Hong Kong market | The three major indices weakened collectively, Meituan fell by more than 5%; auto stocks had mixed ups and downs, and BYD shares reversed the market and rose more than 5%
Biotech stocks weakened, with Corning Jerry Pharmaceuticals falling nearly 45% and Kangfang Biotech falling more than 7%; pharmaceutical stocks fell one after another, with CSPC Group falling nearly 4% and Cinda Biotech falling nearly 3%.
Cinda Biotech's phase III clinical study of picontibalizumab (IBI112) for the treatment of moderate to severe plaque psoriasis reached a major end point and plans to submit a marketing application
San Francisco, China, May 28, 2024/PRNewswire/ -- Cinda Biopharmaceuticals Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as tumors, autoimmunity, metabolism, cardiovascular, and ophthalmology, today announced its self-developed recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection (R&D code: IBI112) in subjects with moderate to severe plaque psoriasis in China (R&D code:) (CLEAR-1) Nakata Owner
US Stock GLP-1 Themed Fund Triggers Thinking: Who Will Be the Next “Novo Nordisk”?
① The GLP-1 themed fund listed last week not only allocates well-known US stocks such as Novo Nordisk and Eli Lilly, but also deals with Hong Kong stocks, Japanese stocks, and European stocks; ② ETF issuers believe that there is plenty of room for growth in the diet medicine market, which is enough for more companies to enter.
Cinda Biotech (1801.HK) 2024 ASCO: Multiple clinical data releases highlight the company's R&D strength
Incident In May 2024, Cinda Biotech published a number of clinical data summaries at the American Society of Clinical Oncology (ASCO) 2024 conference.
Cinda Biotech (1801.HK) Announcement Comment: The marketing application for tetuumab injection has been accepted and commercialization prospects can be expected
Incident: The company announced that the National Drug Administration (NMPA) Drug Evaluation Center (CDE) has officially accepted tetuumab injections (recombinant anti-insulin-like growth factor 1 receptor antibodies (IGF-1R antibodies)).
Hong Kong Stock Concept Tracking | The “upgraded version” of the magic drug for weight loss is here! Eli Lilly's approved domestic industry ushered in a period of breakthroughs and explosions (with concept stocks)
On May 21, Eli Lilai Mu Fengda (tiverpotide injection) was approved by the National Drug Administration (NMPA).
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
Cinda Biotech (01801): The State Drug Administration accepted a new drug marketing application for tetuumab for the treatment of thyroid eye disease
Cinda Biotech (01801) announced that the Drug Evaluation Center of China's State Drug Administration has officially accepted the replacement...
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hong Kong Stock Concept Tracking | Hengrui Pharmaceutical's GLP-1 Products Achieve Active Layout for Foreign Authorized Domestic and Foreign Companies (with Concept Shares)
The wave of research and development of GLP-1 drugs continues to heat up as market demand increases and the development of new drugs advances
Cinda Biotech (01801) GPRC5D/BCMA/CD3 tri-antibody domestic clinical report
The Zhitong Finance App learned that on May 14, according to the CDE official website, Cinda Biotech (01801) IBI3003 Domestic Report Clinical Report (acceptance number: CXSL2400313). IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3. Last year 10 was registered on the ClinicalTrials.gov platform to launch a phase I/II clinical trial. For patients with recurrent or refractory multiple myeloma (registration number: NCT06083207), 116 people were enrolled. The first case was completed in February of this year
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
CEO Yu Dechao reduced his holdings of Cinda Biotech (01801) by about 906,300 shares at a price of about HK$40.37 per share
On May 3, CEO Yu Dechao reduced his holdings of Cinda Biotech (01801) by 9062,500, at a price of HK$40.3726 per share, for a total amount of approximately HK$3.587,700.
UBS: Maintaining Cinda Biotech's (01801) “Buy” Rating Target Price Reduced to HK$57.4
Cinda Biotech (01801) maintains its domestic sales target of RMB 20 billion in 2027.
De-Chao Michael Yu sold 906,300 common shares of Cinda Biotech (01801.HK) worth approximately HK$36.5877 million
On May 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 9, De-Chao Michael Yu sold $9063 million shares of $Cinda Biotech (01801.HK) at an average price of HK$40.3726 per share on May 3, worth approximately HK$36.587,700. After the sale, De-Chao Michael Yu's latest shareholding was 129 million shares, and the good position ratio dropped from 8.00% to 7.94%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding
A quick look at the Hong Kong market | The three major indices rose sharply, and the Tech Index rose nearly 2%; TechNet stocks and Apple concept stocks improved, Meituan rose nearly 4%, and BYD Electronics rose more than 9%
Domestic housing stocks were popular. Shimao Group rose more than 33%, and Sunac China rose 10%; beer stocks rose by many stocks, China Resources Beer rose nearly 5%, and Budweiser Asia Pacific rose 4%.
Head-to-head efficacy with high-dose glycosylating peptides. The first phase III clinical study on diabetes mast peptides reached the end of the study
San Francisco, China, May 9, 2024/PRNewswire/ -- Cinda Biopharmaceuticals Group (HKSE: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as tumors, autoimmunity, metabolism, cardiovascular, and ophthalmology, today announced the phase III clinical study (R&D code: IBI362) of the glucagon-like peptide-1 receptor (GLP-1R) /glucagon receptor (GCGR) dual agonist (R&D code:) in subjects with type 2 diabetes in China (DREAMS-2) Reached the ultimate
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Analysis
Price Target
No Data
